Using tiny carriers to improve cancer treatment with specific drugs
Ultra-Small Epigenetic-Regulating Nanocarrier for Enhanced Synthetic Lethal Therapy
This study is looking at a new way to make cancer treatments work better by using a special drug and tiny carriers to deliver it right to tumors, which could help boost the body's immune response and offer new options for people with different types of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-10979025 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of cancer therapies by combining a drug called 5-azacytidine with PARP inhibitors, which are particularly effective for certain types of cancer. The approach involves developing ultra-small nanocarriers that can deliver these drugs directly to tumors, improving their bioavailability and therapeutic impact. By targeting tumors more effectively, the research aims to increase the immune response against cancer cells and potentially create new treatment options for patients with various cancer types.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors, especially those with BRCA mutations or homologous recombination repair deficiencies.
Not a fit: Patients with cancers that are not solid tumors or those who do not have the specific genetic mutations targeted by this therapy may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments for patients, particularly those with tumors that are currently difficult to treat.
How similar studies have performed: Other research has shown promising results with similar combination therapies, indicating potential for success in this novel approach.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Sun, Jingjing — University of Nebraska Medical Center
- Study coordinator: Sun, Jingjing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.